• Mediwhale

  Participated · Series A · Apr 2023

  Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.

• Kaipharm

  Participated · Series A · Jan 2020

  Kaipham develops next-generation drug discovery technologies using proprietary bioinformatics, big-data mining, and virtual screening driven by AI. Founded in 2018 by Professor Kim Wankyu’s research team, the company focuses on generating high-quality biological and transcriptomic reference data to accelerate target identification, drug repurposing, and toxicity/activity prediction. Its flagship KMAP project aims to build an NGS-based drug-induced transcriptome standard database (KMAP_2K) covering roughly 2,000 compounds including all FDA-approved drugs. Kaipham has a collaborative research agreement with the Korea Pasteur Institute in Pangyo to support the KMAP effort. The company plans to offer joint drug development and analysis services to domestic and international research institutes, universities, and pharmaceutical firms. Financially, Kaipham recently closed a Series A and has secured cumulative funding that includes TIPS and seed investments.

• Insignary

  Participated · Series A · Jan 2018

  Insignary offers a SaaS and server-based security tool, Insignary Clarity™, that enables proactive scanning of software binaries for known security vulnerabilities and potential license compliance issues. Clarity uses a fingerprint-based technology that operates at the binary level without requiring source code or reverse engineering. The company also publishes TruthIsIntheBinary.com and provides cloud-based binary-scanning solutions. BearingPoint made a strategic investment to support Insignary’s growth and go-to-market activities. The funding is intended to help Insignary meet growing demand in the EU, the US and Asia. Insignary is venture-backed and was founded in 2016. Insignary offers Insignary Clarity™, a SaaS and server-based security tool that proactively scans software binaries for known security vulnerabilities and potential license compliance issues. The company’s fingerprint-based technology operates at the binary level without requiring source code or reverse engineering. Its solution is used by software developers, value-added resellers, systems integrators and security managed service providers to oversee deployments and take preventive action before delivery. Led by CEO Tae-Jin (TJ) Kang, Insignary intends to use new capital to scale to meet demand across the E.U., U.S. and Asia for businesses, MSPs, resellers and auditors. Financially, the company secured a $2M Series A and has raised $4M in total venture funding to date. The business is headquartered in Sunnyvale, California.

No current team members are available.